MDT:NYE-Medtronic plc. (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 87.15

Change

+0.23 (+0.26)%

Market Cap

USD 101.99B

Volume

7.58M

Analyst Target

USD 115.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in four operating segments that manufacture and sell device-based medical therapies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 186.58B
SYK Stryker Corporation

N/A

USD 133.55B
BSX Boston Scientific Corp

N/A

USD 107.55B
EW Edwards Lifesciences Corp

N/A

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 26.16B
STE STERIS plc

N/A

USD 21.09B
PHG Koninklijke Philips NV ADR

N/A

USD 18.20B
SNN Smith & Nephew SNATS Inc

N/A

USD 10.70B
BIO Bio-Rad Laboratories Inc

N/A

USD 7.89B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 7.89B

ETFs Containing MDT

CYBG:LSE VanEck Bionic Engineering.. 9.92 % 0.00 %

N/A

USD 6.05M
UMDV:SW iShares US Medical Device.. 9.70 % 0.00 %

N/A

USD 0.18B
CIB0:XETRA VanEck Bionic Engineering.. 9.50 % 0.00 %

N/A

USD 6.36M
FHI:CA CI Health Care Giants Cov.. 5.15 % 0.75 %

N/A

CAD 0.08B
FHI-B:CA CI Health Care Giants Cov.. 5.15 % 0.00 %

N/A

CAD 0.05B
HHL-U:CA Harvest Healthcare Leader.. 4.98 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 4.98 % 0.00 %

N/A

N/A
ABEQ Absolute Core Strategy ET.. 4.52 % 0.00 %

N/A

USD 0.08B
AIVL WisdomTree Trust - Wisdom.. 2.95 % 0.00 %

N/A

USD 0.36B
GDVD Principal Active Global D.. 2.46 % 0.00 %

N/A

USD 0.04B
QUVU 2.33 % 0.00 %

N/A

N/A
DXQ:CA Dynamic Active Enhanced Y.. 2.30 % 0.00 %

N/A

CAD 0.38B
DVND Touchstone ETF Trust - To.. 2.20 % 0.00 %

N/A

USD 0.03B
PUD.B:CA 1.85 % 0.66 %

N/A

N/A
TWAR 1.11 % 0.00 %

N/A

N/A
FUD:CA First Trust AlphaDEX US D.. 0.59 % 0.78 %

N/A

CAD 4.95M
VCLT Vanguard Long-Term Corpor.. 0.08 % 0.07 %

N/A

USD 8.28B
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

N/A

USD 33.72B
BLV Vanguard Long-Term Bond I.. 0.05 % 0.07 %

N/A

USD 5.47B
DTN 0.00 % 0.38 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

USD 5.55B
JDIV 0.00 % 0.12 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
JIGB JPMorgan Corporate Bond R.. 0.00 % 0.14 %

N/A

USD 0.05B
GDNA 0.00 % 0.00 %

N/A

N/A
INAU 0.00 % 0.00 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

N/A

USD 1.09M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD 1.09M
SCHZ Schwab U.S. Aggregate Bon.. 0.00 % 0.04 %

N/A

USD 7.46B
SICK 0.00 % 0.95 %

N/A

N/A
YLD Principal Active High Yie.. 0.00 % 0.65 %

N/A

USD 0.17B
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

CAD 0.33B
XUKS:LSE db x-trackers FTSE 100 Sh.. 0.00 % 0.00 %

N/A

USD 8.61M
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.79% 61% D- 60% D-
Dividend Return 0.84% 100% F 47% F
Total Return 6.63% 61% D- 60% D-
Trailing 12 Months  
Capital Gain 10.07% 60% D- 54% F
Dividend Return 3.49% 100% F 52% F
Total Return 13.55% 60% D- 52% F
Trailing 5 Years  
Capital Gain -4.31% 26% F 38% F
Dividend Return 13.70% 100% F 53% F
Total Return 9.39% 42% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -3.47% 30% F 26% F
Dividend Return -1.04% 30% F 24% F
Total Return 2.43% 100% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 19.11% 90% A- 58% F
Risk Adjusted Return -5.43% 30% F 25% F
Market Capitalization 101.99B 94% A 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.40 91% 28%
Price/Book Ratio 2.14 65% 39%
Price / Cash Flow Ratio 18.38 52% 18%
Price/Free Cash Flow Ratio 14.35 44% 25%
Management Effectiveness  
Return on Equity 8.17% 74% 49%
Return on Invested Capital 5.12% 61% 45%
Return on Assets 4.26% 74% 66%
Debt to Equity Ratio 47.29% 52% 60%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.